The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to ...

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...

Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...

Nate Hill is CEO and Co-Founder of Strive Pharmacy and a national advocate for personalized medicine. With nearly a decade of experience in healthcare, he works to expand access to compounded ...

Pharmaceutical Executive: What is the future of field reps and their relationship with AI? Parth Khanna: Based on our ...

Taken together, Hill's response suggests that restricting access through legitimate compounding channels, without addressing ...

BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall ...

Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment. Pharmaceutical companies have never had access to more ...

President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...

Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment.

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major ...

FDA approved Priovant's Lisraya (brepocitinib) as the first targeted therapy for dermatomyositis, Gilead's Bixlenvo as the ...